Vitamins D and K Effects on Vascular Function in Obese Adults.

Sponsor

Hospital Universitario Pedro Ernesto (Other)

Overall Status

Recruiting

CT.gov ID

NCT05689632

Collaborator

Rio de Janeiro State Research Supporting Foundation (FAPERJ) (Other), Conselho Nacional de Desenvolvimento Científico e Tecnológico (Other)

100

Enrollment

Location

Arms

Anticipated Duration (Months)

6.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A prospective, randomized, placebo-controlled, double-blind study that aims to evaluate the effects of combined vitamin D3 and K2-MK7 supplementation on vascular function, sympathetic tone, metabolic biomarkers and inflammatory factors in a population of overweight or obese adults and deficient or insufficient serum levels of vitamin D.

Condition or Disease	Intervention/Treatment	Phase
Obesity Vitamin D3 Deficiency	Dietary Supplement: Vitamin D3 + K2-MK7 Dietary Supplement: Placebo Dietary Supplement: Vitamin D3	N/A

Detailed Description

Overweight and obesity are public health issues of epidemic proportions nowadays. They constitute risk factors for several chronic diseases with vascular, metabolic, and inflammatory changes. Adequate serum levels of vitamin D are correlated with good cardiovascular and metabolic health, since its deficiency and insufficiency (highly prevalent in obesity) have an inverse correlation. Likewise, vitamin K, especially K2, is related to the reduction of arterial stiffness, suppression of the inflammation in the vascular wall, favorable action on the lipid profile, whereas insufficiency is related to increased cardiovascular risk. The combined use of vitamin D and K aiming to reduce cardiovascular risk has been studied, however, the results of randomized clinical trials are still controversial. This prospective, randomized, placebo-controlled, double-blind trial aims to evaluate the effect of supplementation of vitamins D3 and K2-MK7 on vascular function, sympathetic tone, metabolic biomarkers and inflammatory factors in a population of overweight or obese adults and serum levels of deficient or insufficient vitamin D. Individuals of both sexes, aged between 40 and 70 years, body mass index (BMI) ≥ 25 and < 40 kg/m² and vitamin 25OHD3 <30 ng/ml will be randomized into 3 groups (A/B/C) to receive supplementation (Placebo/VitD3 7000 IU/VitD3 7000IU+K2-MK7-180mcg) daily for 16 weeks. Individuals will be rated at 4 visits namely:

V0 screening according to inclusion and exclusion criteria; clinical, anthropometry and electrical bioimpedance, laboratory and vascular evaluation before supplementation;
V1 supplementation begins;
V2 after 8 weeks;
V3 at the end of the intervention. The laboratory evaluation consists of blood count, biochemistry, electrolytes, glucose, lipid, liver and thyroid profiles, vitamin D3 and parathyroid hormone, in addition to the urinary excretion of calcium and creatinine. Sympathetic tone is assessed by a frequency meter (Polar® Verity Sense), arterial stiffness by measuring the pulse wave velocity by oscillometry (Mobil-O-Graph®) and endothelium function by measuring post-occlusion microvascular reactivity using laser speckle contrast image-LSCI.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

100 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Prospective, randomized, placebo-controlled, double-blind studyProspective, randomized, placebo-controlled, double-blind study

Masking:

Single (Outcomes Assessor)

Masking Description:

The participants and the investigator do not know which supplements are taken.

Primary Purpose:

Treatment

Official Title:

Effects of Vitamin D3 and Vitamin K2MK7 Supplementation on Vascular Function in Overweight or Obese Adults.

Actual Study Start Date :

Jul 15, 2022

Anticipated Primary Completion Date :

Jul 15, 2023

Anticipated Study Completion Date :

Nov 15, 2023

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo Placebo - Medium-chain triglyceride	Dietary Supplement: Placebo MCT
Active Comparator: Vitamin D3 Vitamin D3 - 7000 IU daily	Dietary Supplement: Vitamin D3 Vitamin D3 - 7000 IU
Experimental: Vitamin D3 + K2-MK7 Vitamin D3 - 7000 IU + Vitamin K2-MK7 180mcg combined, daily	Dietary Supplement: Vitamin D3 + K2-MK7 Combined supplementation

Arm

Intervention/Treatment

Placebo Comparator: Placebo

Placebo - Medium-chain triglyceride

Dietary Supplement: Placebo

MCT

Active Comparator: Vitamin D3

Vitamin D3 - 7000 IU daily

Dietary Supplement: Vitamin D3

Vitamin D3 - 7000 IU

Experimental: Vitamin D3 + K2-MK7

Vitamin D3 - 7000 IU + Vitamin K2-MK7 180mcg combined, daily

Dietary Supplement: Vitamin D3 + K2-MK7

Combined supplementation

Outcome Measures

Primary Outcome Measures

Microvascular reactivity [150 minutes]
A laser speckle contrast imaging system with a laser wavelength of 785 nm system will measure non-invasively real time cutaneous microvascular flow changes in the forearm. For the post occlusive reactive hyperemia test, arterial occlusion will be performed with suprasystolic pressure (50 mmHg above the systolic arterial pressure) using a sphygmomanometer applied to the arm of the subject over three minutes. Peak skin flow will be measured after pressure release.

Secondary Outcome Measures

Central blood pressure [150 minutes]
Central systolic blood pressure, diastolic blood pressure, mean arterial pressure and pulse pressure before and after intervention and their potential effects on changes in subendocardial viability ratio and ejection duration after intervention with beetroot juice and water.